The Effectiveness of Glycopyrronium in Drooling Managment: A Scoping Review Protocol
DOI:
https://doi.org/10.12974/2311-8687.2024.12.08Keywords:
Glycopyrronium, Sialorrhea, Drooling, Clinical review, Clinical protocolAbstract
The management of pediatric drooling presents challenges requiring tailored therapeutic approaches. This scoping review examines the efficacy and safety of glycopyrronium in addressing drooling across diverse pediatric populations. Glycopyrronium, an anticholinergic medication, inhibits salivary gland activity, offering promise in managing drooling. Clinical trials and observational studies consistently demonstrate its effectiveness, particularly in children with neurological disabilities like cerebral palsy. Notably, glycopyrronium exhibits efficacy even at lower dosages, emphasizing personalized treatment. However, potential side effects such as dry mouth and vision changes necessitate careful monitoring. Future research should explore predictors of treatment response and include diverse patient populations to optimize management strategies. Overall, glycopyrronium emerges as a valuable therapeutic option for pediatric drooling, improving quality of life for affected children. This review underscores the importance of tailored approaches and highlights the need for further research to enhance outcomes in pediatric drooling management.
References
Miranda-Rius, J.; Brunet-Llobet, L.; Lahor-Soler, E.; Farre, M. Salivary Secretory Disorders, Inducing Drugs, and Clinical Management. Int J Med Sci 2015, 12, 811-824. https://doi.org/10.7150/ijms.12912
Riva, A.; Amadori, E.; Vari, M.S.; Spalice, A.; Belcastro, V.; Viri, M.; Capodiferro, D.; Romeo, A.; Verrotti, A.; Delphi panel experts, g.; et al. Impact and management of drooling in children with neurological disorders: an Italian Delphi consensus. Ital J Pediatr 2022, 48, 118. https://doi.org/10.1186/s13052-022-01312-8
Perinelli, M.; Riva, A.; Federici, C.; Amadori, E.; Viscardi, E.; Terrone, G.; Siri, L.; Verrotti, A.; Striano, P. Comparing Subjective Scales for Rating Drooling: A Pilot, Bicentric, Study. 2022.
Reid, S.M.; Johnson, H.M.; Reddihough, D.S. The Drooling Impact Scale: a measure of the impact of drooling in children with developmental disabilities. Dev Med Child Neurol 2010, 52, e23-28. https://doi.org/10.1111/j.1469-8749.2009.03519.x
Mier, R.J.; Bachrach, S.J.; Lakin, R.C.; Barker, T.; Childs, J.; Moran, M. Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study. Arch Pediatr Adolesc Med 2000, 154, 1214-1218. https://doi.org/10.1001/archpedi.154.12.1214
Riva, A.; Federici, C.; Piccolo, G.; Amadori, E.; Verrotti, A.; Striano, P. Exploring treatments for drooling in children with neurological disorders. Expert Rev Neurother 2021, 21, 179-187.https://doi.org/10.1080/14737175.2021.1855146
Reid, S.M.; Westbury, C.; Guzys, A.T.; Reddihough, D.S. Anticholinergic medications for reducing drooling in children with developmental disability. Dev Med Child Neurol 2020, 62, 346-353. https://doi.org/10.1111/dmcn.14350
Jongerius, P.H.; Rotteveel, J.J.; van den Hoogen, F.; Joosten, F.; van Hulst, K.; Gabreels, F.J. Botulinum toxin A: a new option for treatment of drooling in children with cerebral palsy. Presentation of a case series. Eur J Pediatr 2001, 160, 509-512. https://doi.org/10.1007/s004310100784
Reed, J.; Mans, C.K.; Brietzke, S.E. Surgical management of drooling: a meta-analysis. Arch Otolaryngol Head Neck Surg 2009, 135, 924-931. https://doi.org/10.1001/archoto.2009.110
Peters, M.; Godfrey, C.; McInerney, P.; Munn, Z.; Trico, A.; Khalil, H. Chapter 11: Scoping Reviews. 2020.
https://doi.org/10.46658/JBIRM-20-01
Pubchem. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/3494 (accessed on 29/02/2024).
Lovardi, E.; De Ioris, M.A.; Lettori, D.; Geremia, C.; Staccioli, S.; Bella, G.D.; Scrocca, R.; Scarselli, A.; Aversa, M.; De Peppo, F.; et al. Glycopyrrolate for drooling in children with medical complexity under three years of age. Ital J Pediatr 2022, 48, 2. https://doi.org/10.1186/s13052-021-01195-1
Jongerius, P.H.; van Tiel, P.; van Limbeek, J.; Gabreëls, F.J.; Rotteveel, J.J. A systematic review for evidence of efficacy of anticholinergic drugs to treat drooling. Arch Dis Child 2003, 88, 911-914. https://doi.org/10.1136/adc.88.10.911
Garnock-Jones, K.P. Glycopyrrolate oral solution: for chronic, severe drooling in pediatric patients with neurologic conditions. Paediatric drugs 2012, 14, 263‐269. https://doi.org/10.2165/11208120-000000000-00000
Verdun (QC), P.I. Cuvposa (glycopyrrolate): oral solution 1 mg/5 mL [product monograph]. 2017
Chabicovsky, M.; Winkler, S.; Soeberdt, M.; Kilic, A.; Masur, C.; Abels, C. Pharmacology, toxicology and clinical safety of glycopyrrolate. Toxicol Appl Pharmacol 2019, 370, 154-169. https://doi.org/10.1016/j.taap.2019.03.016
EMA. European Medicines Agency: EMEA/H/C/003883/0000 - Assessment report Sialanar. 2016.
FDA. FDA Approved Drug Products: Cuvposa (Glycopyrronium) Oral Solution.
Blasco, P.A.; Stansbury, J.C. Glycopyrrolate treatment of chronic drooling. Arch Pediatr Adolesc Med 1996, 150, 932-935. https://doi.org/10.1001/archpedi.1996.02170340046009
Stern, L.M. Preliminary study of glycopyrrolate in the management of drooling. J Paediatr Child Health 1997, 33, 52-54. https://doi.org/10.1111/j.1440-1754.1997.tb00991.x
Zeller, R.S.; Lee, H.M.; Cavanaugh, P.F.; Davidson, J. Randomized phase iii evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions. Therapeutics and clinical risk management 2012, 8, 15‐23. https://doi.org/10.2147/TCRM.S26893
Zeller, R.S.; Davidson, J.; Lee, H.M.; Cavanaugh, P.F. Safety and efficacy of glycopyrrolate oral solution for management of pathologic drooling in pediatric patients with cerebral palsy and other neurologic conditions. Ther Clin Risk Manag 2012, 8, 25-32. https://doi.org/10.2147/TCRM.S27362
Parr, J.R.; Todhunter, E.; Pennington, L.; Stocken, D.; Cadwgan, J.; O'Hare, A.E.; Tuffrey, C.; Williams, J.; Cole, M.; Colver, A.F. Drooling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. Arch Dis Child 2018, 103, 371-376. https://doi.org/10.1136/archdischild-2017-313763
Fayoux, P.; Dinomais, M.; Shaw, H.; Villain, F.; Schwartz, D.; Rondeau, S.; Letellier, G.; Auvin, S. Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: a randomized, double-blind, placebo-controlled trial. Developmental medicine and child neurology 2024. https://doi.org/10.1111/dmcn.15841
Bachrach, S.J.; Walter, R.S.; Trzcinski, K. Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. Clinical pediatrics 1998, 37, 485‐490. https://doi.org/10.1177/000992289803700805
Zanon, D.; Tumminelli, C.; Galimberti, A.M.C.; Torelli, L.; Maestro, A.; Barbi, E.; Maximova, N. Compounded glycopyrrolate is a compelling choice for drooling children: five years of facility experience. Ital J Pediatr 2021, 47, 222. https://doi.org/10.1186/s13052-021-01173-7
Drugs.com. Available online: https://www.drugs.com/sfx/glycopyrrolate-side-effects.html (accessed on 29/02/2024).
Operto, F.F.; Pastorino, G.M.G.; Viggiano, A.; Dell'Isola, G.B.; Dini, G.; Verrotti, A.; Coppola, G. Epilepsy and Cognitive Impairment in Childhood and Adolescence: A Mini-Review. Curr Neuropharmacol 2023, 21, 1646-1665. https://doi.org/10.2174/1570159X20666220706102708
